The nurse is about to administer a Category C drug to a pregnant client. Which of the following describes this FDA category of risk potential during pregnancy?
A) A risk has not been documented during pregnancy.
B) Animal studies show no risk, but there is inadequate documentation in humans.
C) Animal studies show adverse affects but there are no adequate studies in humans.
D) There is evidence of human fetal risk, but the benefits may outweigh risks.
C
Feedback:
The following are FDA pregnancy categories: Category A: A risk has not been documented during pregnancy. Category B: Animal studies have not shown a risk, but there is inadequate documentation in humans, OR animal studies have shown adverse effects, but this has not been demonstrated in humans. Category C: Animal studies have shown adverse effects, but there are no adequate studies in humans, OR the benefits to the pregnant woman may outweigh potential risks, OR there are no adequate studies in humans or animals. Category D: There is evidence of human fetal risk, but the benefits may outweigh potential risks. Category X: Abnormalities have been documented the risk of use in pregnant women precludes the use of this medication.
You might also like to view...
The nurse is assessing a client who presents to the emergency department after recently being discharged from the hospital after a right above-the-knee amputation
The client tells the nurse that her right foot hurts. Which type of pain does the nurse suspect that this client is experiencing? 1. Phantom pain. 2. Radiating pain. 3. Intractable pain. 4. Cutaneous pain.
The Diffusion of Innovations Theory was developed by Stetler
A) True B) False
A nurse is assessing a 77-year-old male admitted to the unit for suspected liver dysfunction. What assessment finding will the nurse expect to find?
A) Liver function results change dramatically in the older adult. B) Metabolism of medications is delayed primarily by the liver. C) The liver is enlarged with hard edges. D) The liver is decreased in size and weight.
Carbamazepine has a Black Box Warning recommending testing for the HLA-B*1502 allele in patients with Asian ancestry prior to starting therapy due to:
1. Decreased effectiveness of carbamazepine in treating seizures in Asian patients with the HLA-B*1502 allele 2. Increased risk for drug interactions in Asian patients with the HLA-B*1502 allele 3. Increased risk for Stevens-Johnson syndrome in Asian patients with HLA-B*1502 allele 4. Patients who have the HLA-B*1502 allele being more likely to have a resistance to carbamazepine